Cardioprotective Effects of LCZ696 (Sacubitril/Valsartan) After Experimental Acute Myocardial Infarction

LCZ696 (sacubitril/valsartan) can lower the risk of cardiovascular events in chronic heart failure. However, it is unclear whether LCZ696 can improve prognosis in patients with acute myocardial infarction (MI). The present study shows that LCZ696 can prevent cardiac rupture after MI, probably due to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Masanobu, Kaikita, Koichi, Sato, Koji, Sueta, Daisuke, Fujisue, Koichiro, Arima, Yuichiro, Oimatsu, Yu, Mitsuse, Tatsuro, Onoue, Yoshiro, Araki, Satoshi, Yamamuro, Megumi, Nakamura, Taishi, Izumiya, Yasuhiro, Yamamoto, Eiichiro, Kojima, Sunao, Kim-Mitsuyama, Shokei, Ogawa, Hisao, Tsujita, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
PRECLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059351/
https://www.ncbi.nlm.nih.gov/pubmed/30062181
http://dx.doi.org/10.1016/j.jacbts.2017.08.001
Descripción
Sumario:LCZ696 (sacubitril/valsartan) can lower the risk of cardiovascular events in chronic heart failure. However, it is unclear whether LCZ696 can improve prognosis in patients with acute myocardial infarction (MI). The present study shows that LCZ696 can prevent cardiac rupture after MI, probably due to the suppression of pro-inflammatory cytokines, matrix metalloproteinase-9 activity and aldosterone production, and enhancement of natriuretic peptides in mice. These findings suggest the mechanistic insight of cardioprotective effects of LCZ696 against acute MI, resulting in the belief that LCZ696 might be useful clinically to improve survival after acute MI.

Ejemplares similares